Key points are not available for this paper at this time.
Introduction: Postpartum haemorrhage is the most serious complication in obstetric practice. The greatest number of maternal deaths from haemorrhage is due to PPH, which is almost entirely a preventable condition. WHO defines PPH as blood loss of 500 ml or more in first 24 hours post-partum. PPH is one of the most common obstetric maternal complications and is among the three most common etiologies of maternal death worldwide. Objective: To compare misoprostol versus oxytocin in reducing postpartum hemorrhage after labor induction. Methods: The study was a randomized clinical trial carried out at the Department of Gynaecology (P= 0.11). The mean duration of third stage of labor was similar and the difference was not statistically significant (6.65±3.47 vs. 6.08±3.07 minutes) (P=0.38), as well as need for additional oxytocics (14.5% vs. 7.2% P=0.18) misoprostol and oxytocin, respectively. In misoprostol group, side effects were shivering, fever, nausea and abdominal pains, while the oxytocin group abdominal pains, headaches and shivering. Conclusion: Sublingual misoprostol has similar efficacy to standard intramuscular oxytocin in the active management of third stage of labor. This study also revealed that a 200 µg tablet may be as effective as the previously investigated higher doses. Thus, misoprostol at 200 µg with its thermo stability may be an effective alternative to intramuscular oxytocin in active management of third stage of labor.
Akter et al. (Wed,) studied this question.